sh-vector-shutterstock-com-1
SH-Vector / Shutterstock.com
10 September 2015Big PharmaClaire Phipps-Jones

London calling: the benefits of the UPC’s new home

The announcement on August 11 of the location of the London central division of the Unified Patent Court (UPC) should be welcomed by the life sciences sector. Not only is the new court at Aldgate Tower in the middle of legal London and a stone’s throw from MedCity (the organisation managing a life sciences cluster including London, Cambridge and Oxford), it’s also easily accessible to the hotbed of innovators and manufacturers based in London and the south-east and to international court users alike.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
27 November 2025   Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.
Big Pharma
20 November 2025   A new report from Clarivate highlights a jump in the tech’s adoption among IP professionals over the past two years, as well as concerns over governance.
Big Pharma
10 November 2025   According to new research, generic and brand-name pharma companies are ramping up ANDA litigation with Sun Pharma and Bristol Myers Squibb leading the charge.